Chief Commercial Officers · Jade Biosciences, Inc. (JBIO)

Timothy Pigot

FY2023 is the first fiscal year CompBrief holds for Timothy Pigot as a named executive officer of Jade Biosciences; the record below is that year, complete. Every figure below is printed as the company filed it and cited to the filing it came from.

Total disclosed compensation, FY2023

$2,453,576

Salary $395,000

2nd of 3 named executive officers at Jade Biosciences by FY2023 total.

3 named officers on file for Jade Biosciences, FY2023

Timothy Pigot’s pay file — $29

  • 1 fiscal year of pay, line by line
  • JBIO’s disclosed peer group of 20 companies

A PDF and a CSV sent to your email. Every row is cited to its filing.

One-time report. No refunds.

See an example →

Velarion Intel · free for 3 days · no card

See how Jade Biosciences’s whole pay program stands against its peers

  • Jade Biosciences’s company dashboard and its AI-written, board-ready brief, every figure cited to the filing
  • Peer-group intelligence, custom peer reruns and governance screens
  • Every other company we cover, with alerts when they file
Start my free trial on JBIO→

No card. Nothing is charged, and the trial ends on its own.

Compensation figures as of the proxy filed April 26, 2024 (DEF 14A).

Free

Get Timothy Pigot’s pay history as a PDF, right here and by email

The PDF adds what this page leaves out: up to 10 years of pay, a peer comparison, and the board on one page. Two emails at most, nothing else.

Timothy Pigot compensation by year

Jade Biosciences Summary Compensation Table · the one fiscal year held
In US dollars, as Jade Biosciences reports it. Most recent year shaded. Totals are the company’s disclosed totals.
ComponentFY2023
Salary$395,000
Option awards$1,868,976
Non-equity incentive$189,600
All other$0
Total$2,453,576

Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Jade Biosciences, Inc. DEF 14A filed April 26, 2024, accession 0001798749-24-000022, and prior-year filings. Open the filing on EDGAR.

How this page was built: the Jade Biosciences, Inc. filed document, accession 0001798749-24-000022. Every figure is read from that document and cited to the page and table it appears in. Filed April 26, 2024.

Equity holdings

unvested awards at FY2023 year-end
TypeUnvested unitsValue at year-endExercise price
Option28,875—$14.00
Option58,584—$25.57
Option15,000—$10.61

Per the Outstanding Equity Awards at Fiscal Year-End table in Jade Biosciences, Inc.'s FY2023 proxy; value at the fiscal year-end close, as the company printed it.

Jade Biosciences’s named executive officers, FY2023

as the company reported each
Named executive officerRoleFY2023 total
Timothy NoyesChief Executive Officer$3,070,657
Timothy Pigot · this pageChief Commercial Officers$2,453,576
George EldridgeChief Financial Officer$2,132,823

The full Jade Biosciences compensation record

free company brief

This page is one person within Jade Biosciences's record. The company brief lists every named executive, each linking to their own page.

Compensation, the day it’s disclosed

The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them.

How this record is built

Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Jade Biosciences's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.

Timothy Pigot's compensation dossier · One-time report. No refunds.